Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience

Mansoor, Neelum; Jabbar, Naeem; Arshad, Uzma; Maqsood, Sidra; Habib, Muhammad A.; Raza, Muhammad Rafie

doi:10.1097/mph.0000000000001853

Cited by 4 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the percentage of chloroma was lower in patients with inv(16) than those with t(8; 21), and this was never been reported before. In accordance with previous studies, when referred to relapse, BM relapse and CNS relapse were more frequent in patients with inv(16) than those with t(8; 21) [ 7 – 9 ].…”

Section: Discussionsupporting

confidence: 92%

Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Qiu

Liao

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

Purpose To explore the outcome and prognostic factors between inv(16) and t(8;21) disrupt core binding factor (CBF) in acute myeloid leukemia (AML). Methods The clinical characteristic, probability of achieving complete remission (CR), overall survival (OS) and cumulative incidence of relapse (CIR) were compared between inv(16) and (8;21). Results The CR rate was 95.2%, 10-year OS was 84.4% and CIR was 29.4%. Subgroup analysis showed that patients with t(8;21) had significant lower 10-year OS and CIR than patients with inv(16). Unexpectedly, there was a trend for pediatric AML receiving five courses cytarabine to have a lower CIR than four courses cytarabine (19.8% vs 29.3%, P = 0.06). Among the cohort of no-gemtuzumab ozogamicin(GO) treatment, inv (16) patients showed a similar 10-year OS (78.9% vs 83.5%; P = 0.69) and an inferior outcome on 10-year CIR (58.6% vs 28.9%, P = 0.01) than those patients with t(8;21). In contrast, inv (16) and t(8;21) patients receiving GO treatment had comparable OS (OS: 90.5% vs. 86.5%, P = 0.66) as well as CIR (40.4% vs. 21.4%, P = 0.13). Conclusion Our data demonstrated that more cumulative cytarabine exposure could improve the outcome of childhood patients with t(8;21), while GO treatment was beneficial to the pediatric patients with inv(16).

show abstract

Section: Discussionsupporting

confidence: 92%

Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Qiu

Liao

et al. 2023

BMC Cancer

View full text Add to dashboard Cite

show abstract

“… 26 In another study, in acute myeloid leukaemia, nearly 25% of the patients showed the core-binding factor associated with translocations. 27 In the USA, recent germline genomic studies have revealed that at least 5%–10% of children with cancer and nearly 3%–4% with acute lymphoblastic leukaemia, develop the disease due to an underlying genetic predisposition. 28 Further, in a report from China, the two most important factors identified for childhood leukaemia are exposure to hydrocarbons and ionising radiation.…”

Section: Discussionmentioning

confidence: 99%

Cancer in Lahore, Pakistan, 2010–2019: an incidence study

Badar

Mahmood

2021

BMJ Open

View full text Add to dashboard Cite

ObjectivesTo study the cancer incidence rates over 10 years (2010–2019), in Lahore, Pakistan.DesignAn incidence study.SettingThe population-based Punjab Cancer Registry was established in 2005 in Lahore, which is the provincial metropolis of the province of Punjab (five rivers), and is located in the northeast region of Pakistan. The coordinating office of the Registry is located within Shaukat Khanum Memorial Cancer Hospital and Research Center. Both the active and passive forms of data collection are used.ParticipantsResidents of the district of Lahore diagnosed with cancer. The average annual population of Lahore was estimated at 11.1 million.Outcome measuresCancer counts and incidence rates per 100 000 population, by age-group, sex and cancer site/type, over 10 years.ResultsIn Lahore, from 2010 to 2019, 58 394 incident cases were reported, with the majority seen in females (57.1%). Adults accounted for 92.2%, adolescents 2.2% and children 5.6% of the total cases. Per 100 000 population, the age-standardised incidence rate was 103.4 for females and 65.6 for males. Among females, the highest incidence rates were recorded for breast cancer (76.7) in adults, bone tumour (1.2) in adolescents and lymphoid leukaemia (1.6) in children, and among males, prostate cancer (10.7) in adults, bone tumour (2.2) in young adults and lymphoid leukaemia (2.4) in children. The age-specific incidence rates peaked in the 60–70 year group, reaching a high of 420 per 100 000 in women and 330 per 1 00 000 men.ConclusionsIn Lahore, the incidence rates for cancers of the breast, prostate, lymphoid leukaemia and bone were among the highest documented. More cases were recorded in females than in males. The results reported could be used as a reference point for assessing the effectiveness of future interventions.

show abstract

“…Median overall survival (OS) of favorable group was 51 (range 20-79) weeks (95%CI 41. 3 weeks (95% CI 38.6 to 49.3), respectively. There was no statistical different of survival rate between favorable and unfavorable groups (P value of DFS and OS were 0.161 and 0.120, respectively) (Figure 2).…”

Section: Resultsmentioning

confidence: 98%

“…The CBF-AML includes 2 major subtypes of favorable group, translocation t(8;21)(q22;q22), and inversion of chromosome 16 (inv(16)(p13q22)), which together account for 25% of pediatric de novo AML patients. 3 Berlin-Frankfurt-Munster (BFM) study groups and Medical Research Council (MRC) haves confirmed the overall survival (OS) rate of t(8;21) and inv(16) mutation in childhood CBF AML were 91% and 92%, respectively. 4 This study was conducted to evaluate the role of karyotype abnormalities t(8,21) and inv(16) as favorable prognostic factors of complete remission after induction phase chemotherapy in pediatric AML.…”

mentioning

confidence: 98%

Role of cytogenetic profiles as prognostic factors for complete remission after induction phase in acute myeloblastic leukemia

Sjakti¹,

Gatot²,

Wahidiyat³

et al. 2021

View full text Add to dashboard Cite

Background Risk stratification for acute myeloid leukemia (AML) in children is a must in treatment strategy. This stratification is based on cytogenetic profiles, which are needed to determine proper management to gain better outcomes and reduce side effects of treatment. There is no such risk stratification available in Indonesia until now. Objective To evaluate the association between cytogenetic profiles of t(8,21) and inv(16) mutations with the complete response to induction phase of chemotherapy in pediatric AML. Methods A prospective study was conducted between year 2018 and 2020, involving children with AML from 4 pediatric oncology centers in Jakarta. Subjects were evaluated for cytogenetic profiles, especially t(8,21) and inv(16), as the favorable predictors for AML. Bone marrow remission was evaluated after 2 cycles of induction phase. The results were evaluated for remission rate and survival analysis. Results Karyotype data of 18 subjects were obtained. Translocation t(8;21) detected in 1 subject, and inv(16) mutation in 4 subjects. These two variables had no significant correlation with complete remission after induction phase. Nevertheless, favorable group had more tendencies to achieved remission than unfavorable group. Complete remission achieved in 61% subjects, 90% of theme had a relapse period with an average time 43 weeks. The relapse period in favorable group was shoter than in unfavorable group (34 weeks and 44 weeks, respectively). Conclusions This study shows that cytogenetic profiles of t(8;21) and inv(16) mutation can not be used as prognostic factors for complete remission after induction phase of chemotherapy in pediatric AML.

show abstract

Outcome of Core Binding Factor Acute Myeloid Leukemia in Children: A Single-Center Experience

Cited by 4 publications

References 23 publications

Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

Cancer in Lahore, Pakistan, 2010–2019: an incidence study

Role of cytogenetic profiles as prognostic factors for complete remission after induction phase in acute myeloblastic leukemia

Contact Info

Product

Resources

About